Maria Chiara Gerardi1, Melissa Alexandre Fernandes2, Angela Tincani1, Laura Andreoli3. 1. Rheumatology and Clinical Immunology Unit and Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy. 2. Autoimmune Disease Unit-Department of Internal Medicine, Hospital Curry Cabral/Centro Hospitalar Lisboa Central, Lisbon, Portugal. 3. Rheumatology and Clinical Immunology Unit and Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy. laura.andreoli@unibs.it.
Abstract
PURPOSE OF REVIEW: This review focuses on new pathogenesis and clinical-therapeutic aspects of obstetric anti-phospholipid syndrome (ob-APS) in the last 5 years. RECENT FINDINGS: The pathogenesis of ob-APS is multifactorial, including placental infarctions, infiltration of inflammatory cells that cause acute and chronic inflammation, leading to uncontrolled inflammation and poor pregnancy outcomes. A preconception counseling and a patient-tailored treatment are fundamental to improve maternal and fetal outcomes. Thanks to conventional treatment, based on low-dose aspirin and heparin, 70% of women with ob-APS can have successful pregnancies. Women with positive anti-phospholipid antibodies (aPL) without clinical manifestations ("aPL carriers") or with obstetric manifestation not fulfilling ob-APS criteria need to be further investigated in order to assess their best management. Great interest has been given to drugs that could interact in the pathophysiological mechanisms, such as hydroxychloroquine, statins, and eculizumab. These drugs could be considered for patients refractory to conventional therapy.
PURPOSE OF REVIEW: This review focuses on new pathogenesis and clinical-therapeutic aspects of obstetric anti-phospholipid syndrome (ob-APS) in the last 5 years. RECENT FINDINGS: The pathogenesis of ob-APS is multifactorial, including placental infarctions, infiltration of inflammatory cells that cause acute and chronic inflammation, leading to uncontrolled inflammation and poor pregnancy outcomes. A preconception counseling and a patient-tailored treatment are fundamental to improve maternal and fetal outcomes. Thanks to conventional treatment, based on low-dose aspirin and heparin, 70% of women with ob-APS can have successful pregnancies. Women with positive anti-phospholipid antibodies (aPL) without clinical manifestations ("aPL carriers") or with obstetric manifestation not fulfilling ob-APS criteria need to be further investigated in order to assess their best management. Great interest has been given to drugs that could interact in the pathophysiological mechanisms, such as hydroxychloroquine, statins, and eculizumab. These drugs could be considered for patients refractory to conventional therapy.
Authors: V Pengo; A Ruffatti; M Tonello; A Hoxha; E Bison; G Denas; S Padayattil Jose; G Zoppellaro; A Bracco; A Banzato Journal: Thromb Res Date: 2015-05-01 Impact factor: 3.944
Authors: Katarina Jeremic; Aleksandar Stefanovic; Jelena Dotlic; Jelena Stojnic; Sasa Kadija; Zoran Vilendecic; Tijana Janjic; Jelena Jeremic Journal: J Perinat Med Date: 2015-11 Impact factor: 1.901
Authors: Gayane Manukyan; Anush Martirosyan; Ludek Slavik; Jana Ulehlova; Martin Dihel; Tomas Papajik; Eva Kriegova Journal: Biomedicines Date: 2020-06-15